SciSparc-Clearmind Publish Innovative Ketamine Combo Application

SciSparc Ltd., a clinical-stage pharmaceutical company based in TEL AVIV, Israel, has announced a significant development in its collaboration with Clearmind Medicine Inc. Clearmind, a biotechnology firm, focuses on the discovery and development of therapeutic solutions derived from psychedelic substances to address under-treated mental health issues. Recently, Clearmind publicized its patent application under the international Patent Cooperation Treaty for novel combinations of ketamine and N-acylethanolamines.

In their joint research, SciSparc and Clearmind are exploring treatment combinations that involve SciSparc’s Palmitoylethanolamide (PEA) and Clearmind’s innovative psychedelic compound, MEAI. This collaboration aims to develop therapies for addictions, weight management, and mental health disorders. Additionally, the partnership is investigating new treatments that combine psychedelic molecules with PEA. So far, thirteen patents related to this endeavor have been filed with the U.S. Patent and Trademark Office and various international patent offices.

The U.S. Food & Drug Administration (FDA) had previously approved a derivative of ketamine for use as a nasal spray medication in 2019. This treatment is intended for adult patients suffering from depression that has not been alleviated by other treatments or those experiencing major depressive disorder with suicidal thoughts or behaviors. The administration of this treatment is strictly regulated; it must be carried out in certified medical facilities and used in conjunction with an antidepressant. After receiving the medication, patients must stay at the facility for a two-hour observation period to monitor for any serious side effects.

Oz Adler, the Chief Executive Officer of SciSparc, emphasized the company's commitment to developing unique and proprietary combinations involving PEA. According to Adler, research has demonstrated that PEA can significantly reduce the dosage of various active ingredients while maintaining their effectiveness and minimizing adverse effects. He noted that ketamine, approved by the FDA, requires close supervision due to its potential side effects. SciSparc's innovative approach aims to provide therapeutic benefits to a broad range of patients with different conditions, while also minimizing unwanted side effects. Adler believes that this approach could enhance treatment outcomes across a wide spectrum of medical needs.

SciSparc Ltd. is a specialized clinical-stage pharmaceutical company driven by a team of experienced executives and scientists. The company's primary focus is on developing and enhancing a portfolio of cannabinoid-based pharmaceuticals. SciSparc is currently engaged in several drug development programs that utilize THC and/or non-psychoactive cannabidiol. These programs include SCI-110, which is being developed for the treatment of Tourette Syndrome and Alzheimer’s disease agitation, and SCI-210, which targets autism and status epilepticus. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!